Unlocking The Value Of AI In IRT: Practical Perspectives From Vendors

By Carrie Crawford, Vice President, Study Delivery, Endpoint Clinical, and Brett Castano, Director, Clinical Supply Systems, Moderna

Artificial intelligence is rapidly gaining traction across clinical trial technology, yet its role in Interactive Response Technology (IRT) is still widely misunderstood. While AI can add substantial value by improving forecasting accuracy, automating supply chain decisions, and reducing manual intervention, successful adoption requires far more than implementing advanced algorithms. Vendors consistently highlight the need for high-quality data, strong regulatory alignment, and well-defined governance frameworks to ensure AI-enabled processes remain transparent, traceable, and compliant. Emerging applications already demonstrating promise include predictive modeling for drug supply, adaptive trial adjustments informed by real-time data, and intelligent monitoring that mitigates risk while increasing operational efficiency. At the same time, challenges such as algorithmic bias, integration complexity, validation expectations, and building stakeholder trust must be proactively addressed to achieve meaningful impact.

For organizations considering AI in IRT, understanding these vendor perspectives is essential for developing strategies that balance innovation with reliability. Read the full piece to explore how AI is reshaping IRT and the practical steps needed for responsible, effective implementation.